Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives $9.50 Consensus Target Price from Analysts

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) have been assigned an average rating of “Moderate Buy” from the nine analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $9.50.

A number of research firms have recently commented on XERS. Wall Street Zen cut Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Saturday, November 8th. Oppenheimer reaffirmed an “outperform” rating and issued a $18.00 price objective on shares of Xeris Biopharma in a research report on Friday, November 7th. Piper Sandler lifted their target price on Xeris Biopharma from $6.00 to $8.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Xeris Biopharma in a research note on Friday, January 9th. Finally, Barclays began coverage on shares of Xeris Biopharma in a report on Monday, December 8th. They issued an “overweight” rating and a $9.00 price target on the stock.

Xeris Biopharma Stock Up 1.2%

XERS stock opened at $7.61 on Wednesday. Xeris Biopharma has a twelve month low of $3.21 and a twelve month high of $10.08. The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of -76.09 and a beta of 0.50. The firm’s fifty day simple moving average is $7.23 and its two-hundred day simple moving average is $7.34.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.00 EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.01). The company had revenue of $74.38 million for the quarter, compared to analysts’ expectations of $74.19 million. As a group, equities research analysts expect that Xeris Biopharma will post -0.41 EPS for the current year.

Insider Buying and Selling at Xeris Biopharma

In other news, Director Barbara-Jean A. Bormann-Kennedy sold 15,000 shares of Xeris Biopharma stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $7.09, for a total transaction of $106,350.00. Following the completion of the sale, the director owned 142,500 shares of the company’s stock, valued at approximately $1,010,325. The trade was a 9.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Kevin Mcculloch sold 15,000 shares of the stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $8.00, for a total value of $120,000.00. Following the completion of the transaction, the insider directly owned 1,685,426 shares in the company, valued at approximately $13,483,408. This trade represents a 0.88% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 263,550 shares of company stock valued at $1,917,672. 4.56% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. UBS Group AG increased its holdings in shares of Xeris Biopharma by 682.4% in the 3rd quarter. UBS Group AG now owns 1,782,734 shares of the company’s stock valued at $14,511,000 after acquiring an additional 1,554,869 shares during the period. Qube Research & Technologies Ltd boosted its position in Xeris Biopharma by 67.5% during the second quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company’s stock valued at $14,429,000 after purchasing an additional 1,245,188 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after purchasing an additional 1,199,435 shares in the last quarter. CenterBook Partners LP grew its stake in Xeris Biopharma by 237.7% in the second quarter. CenterBook Partners LP now owns 1,594,229 shares of the company’s stock valued at $7,445,000 after purchasing an additional 1,122,154 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in Xeris Biopharma by 108.3% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,227,959 shares of the company’s stock worth $5,735,000 after purchasing an additional 638,488 shares in the last quarter. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.